Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “FMRFamide”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources

Biochemical and immunocytological localization of the neuropeptides FMRFamide, SCPA, SCPB, to neurons involved in the regulation of feeding in Aplysia.

The localization of the neuropeptide FMRFamide in the buccal ganglia and buccal muscles of Aplysia was studied by immunocytology and high-pressure liquid chromatography (HPLC) combined with either a sensitive bioassay or 35S-methionine labeling. Immunocytology with an antiserum directed to FMRFamide stained a large number of fibers, varicosities, and neuronal somata. Two groups of stained neurons were of particular interest. One was the S cells, a group comprised of many small neurons, the majority of which were stained. HPLC of pooled labeled S cells confirmed that at least some of these neurons synthesize FMRFamide. The other group of stained neurons were in the ventral cluster, a group comprised of a small number of large neurons, many of which are motor neurons that innervate the buccal muscles involved in producing biting and swallowing movements. Several of the ventral neurons were previously shown to contain 2 other neuropeptides, the small cardioactive peptides SCPA and SCPB. These neurons are sufficiently large to permit HPLC analyses of the neuropeptides synthesized by individual neurons. This procedure confirmed that individual ventral neurons synthesized FMRFamide, or the SCPs, or all 3 peptides. The coexistence of FMRFamide and the SCPs in the same neuron was confirmed by simultaneous staining of sections from the buccal ganglia with a monoclonal antibody to the SCPs and an antiserum to FMRFamide. The coexistence of the 3 peptides in the same neuron was surprising in light of the observations that these peptides often have opposite biological activity. The ventral neurons are large and potentially identifiable as individuals. Thus, these neurons may be particularly useful for studying the physiological and behavioral roles of neuropeptides in generating complex behaviors.

Animals↗

The molluscan neurosecretory peptide FMRFamide: comparative pharmacology and relationship to the enkephalins.

The molluscan neuropeptide FMRFamide (Phe-Met-Arg-Phe-NH2) has diverse actions on excitable tissues of molluscs, including hearts, noncardiac muscles, complex organs, and neurons. The intracellular transducing mechanisms are also diverse and are not readily correlated with particular responses. FMRFamide increases cyclic AMP levels concomitant with both cardioexcitation and inhibition, but not with muscle contraction. In the same tissues, the effects of 5-hydroxytryptamine are dissimilar and are always accompanied by a cyclic AMP increase. FMRFamide and acetylcholine cause similar tonic contractions of the Busycon radula protractor muscle and identical catch contractures of the mytilid anterior byssus retractor muscle, but the ionic basis of excitation and the sources of activator calcium for contraction are not the same for the two agonists. A comparative study of structure-activity relations showed that FMRFamide receptors are heterogeneous. Helix aspersa ganglia contain no FMRFamide, but a close analog occurs and has been tentatively identified. Evidence supporting a proposed homology between FMRFamide-like and opioid peptides is summarized. The effects of the amphiactive heptapeptide Tyr-Gly-Gly-Phe-Met-Arg-Phe-NH2 on the venus clam rectum support this hypothesis.

Acetylcholine↗

Effect of neuropeptide FMRFamide on immobile behavior in rats.

In the forced swimming induced immobility test, neuropeptide FMRFamide (5-20 micrograms) administered via the intracerebroventricular (icv) route, prolonged immobilization period in rats. On the other hand, immunoneutralization of endogenous FMRFamide by its antiserum (1 microliter, icv) significantly reduced the duration of immobility. Intraperitoneal administration of amitriptyline (3 mg/kg), imipramine (5 mg/kg), fluoxetine (5 mg/kg) or amphetamine (0.5 mg/kg) attenuated FMRFamide-induced prolongation of immobility. Biochemical studies indicated that FMRFamide treatment had significant effects on rat brain monoamines. FMRFamide significantly lowered the brain levels of 5-hydroxytryptamine and norepinephrine in the doses that prolonged the immobility. These results that FMRFamide prolongs the duration of immobility, perhaps by modulating the release of neurotransmitters like 5-hydroxytryptamine and/or norepinephrine.

Amino Acid Sequence↗

Distribution of FMRFamide-like immunoreactivity in the brain and pituitary of Rana esculenta during development.

Developmental aspects of the distribution of FMRFamide (Phe-Met-Arg-Phe-NH2) immunoreactivity (ir) were investigated by indirect immunofluorescence in the brain, pituitary and terminal nerve of the frog, Rana esculenta. Soon after hatching. FMRFamide neurons were found in the proximal terminal nerve, mediobasal olfactory bulb, caudal dorsolateral pallium, diagonal band of Broca, anterior preoptic area, suprachiasmatic area, thalamus, infundibulum, and developing pituitary. FMRFamide fibers were present in the olfactory epithelium, terminal nerve, olfactory bulbs, dorsal and midventral telencephalon, epiphysis, mediolateral thalamus, pretectal gray, optic tectum, infundibulum, posterior interpeduncular nucleus-tegmentum area, and rostral rhombencephalon. During successive developmental stages, ir neurons were no longer observed in the dorsal telencephalon and pituitary. In late larval stages, ir neurons appeared in the medial septal area, and ir fibers in the cerebellum and torus semicircularis. At the same time, the frequency of ir neurons increased progressively in the anterior preoptic area, suprachiasmatic area and infundibulum. FMRFamide-ir neurons were never revealed in mesencephalon and rhombencephalon. Numerous ir fibers terminated in the median eminence and intermediate lobe of the pituitary. The adult pattern of distribution of FMRFamide-ir elements in the brain was achieved during the postmetamorphic development. In light of the existing literature, the possible placodal origin of forebrain-located FMRFamide neurons is briefly discussed.

Animals↗

Regulation of Drosophila FMRFamide neuropeptide gene expression.

Physiologically important peptides are often encoded in precursors that contain several gene products; thus, regulation of expression of polypeptide proteins is crucial to transduction pathways. Differential processing of precursors by cell- or tissue-specific proteolytic enzymes can yield messengers with diverse distributions and dissimilar activities. FMRFamide-related peptides (FaRPs) are present throughout the animal kingdom and affect both neural and gastrointestinal functions. Organisms have several genes encoding numerous FaRPs with a common C-terminal structure but different N-terminal amino acid extensions. We have isolated SDNFMRFamide, DPKQDFMRFamide, and TPAEDFMRFamide contained in the Drosophila FMRFamide gene. To investigate the regulation of expression of FMRFamide peptides, we generated antisera to distinguish among the three neuropeptides. We have previously reported the distribution of SDNFMRFamide and DPKQDFMRFamide. In this article, we describe TPAEDFMRFamide expression. TPAEDFMRFamide antisera stain cells in embryonic, larval, pupal, and adult thoracic and abdominal ganglia. In addition, TPAEDFMRFamide-immunoreactive material is present in a lateral protocerebrum cell in adult. Thus, TPAEDFMRFamide antisera staining of neural tissue is different from SDNFMRFamide or DPKQDFMRFamide. In addition, TPAEDFMRFamide antisera stain larval, pupal, and adult gut, while SDNFMRFamide and DPKQDFMRFamide do not. TPAEDFMRFamide immunoreactivity is present in cells stained by FMRFamide antisera. Taken together, these data support the conclusion that TPAEDFMRFamide is differentially processed from the FMRFamide polypeptide protein precursor and may act in both neural and gastrointestinal tissue.

Animals↗

FMRFamide-like material in the earwig, Euborellia annulipes, and its functional significance.

The neurosecretory system of the earwig, Euborellia annulipes, contained material similar to that of FMRFamide, as shown by immunocytochemistry. Within the brain were two pairs of darkly staining perikarya in the medial protocerebrum, and up to four pairs of immunoreactive cells in the lateral protocerebrum. The corpora allata appeared immunoreactive in 10-day females, but not in 2-day-old adults. Additionally, immunoreactive material was detected in midgut endocrine cells of both 2- and 10-day-old females. FMRFamide at 1 to 100 nM did not inhibit juvenile hormone production by earwig corpora allata in vitro. This was true of glands of low activity from 2-day cat food-fed or starved virgin females, 10-day starved females, and those of relatively high activity from 10-day-old, cat food-fed females. In contrast, FMRFamide at 50 and 100 (but not at 1) nM stimulated gut motility in vitro in distended guts from 2-day fed females. Preparations from starved females and those from 10-day fed females (in which feeding behavior is on the decline) did not respond to exogenous FMRFamide with enhanced rates of contraction. Lastly, preparations from females starved for 7 days and subsequently fed for 3 days responded to 10 nM FMRFamide with increases in gut motility.

Animals↗

Neuropeptide-FMRFamide-like immunoreactivity in Drosophila: development and distribution.

Neuropeptide-FMRFamide-like immunoreactivity was characterized in the fruit fly, Drosophila melanogaster. In the adult central nervous system, a stereotypic pattern of immunoreactive cell bodies and immunoreactive nerve processes and varicosities was observed, indicating a neurochemical role for FMRFamide-like substance(s) in Drosophila. Localization of immunoreactivity in the central nervous system of early larval stage revealed that the majority of the prominent FMRFamide-like immunoreactive neurons were already differentiated. The FMRFamide-like immunoreactive neurons remain immunoreactive throughout postembryonic stage and persist in the adult central nervous system. In the larva, in addition to the central nervous system, FMRFamide-like immunoreactivity was localized in the fibers innervating the ring gland, in the ganglion innervating the gut and in the gastric caeca.

Animals↗

In situ hybridization analysis of the FMRFamide neuropeptide gene in Drosophila. II. Constancy in the cellular pattern of expression during metamorphosis.

We have studied changes in the pattern of specific neuropeptide gene expression during the metamorphosis of the Drosophila nervous system. Prior to metamorphosis, the Drosophila FMRFamide gene is expressed exclusively within the central nervous system in a stereotyped pattern that comprises roughly 60 neurons (Schneider et al., '91). Using in situ hybridization, we found that the FMRFamide gene was continuously expressed throughout all stages examined: at each of 15 stages of adult development and through at least the first 10 days of adult life. There were no differences between the results observed with 2 exon-specific hybridization probes, thus indicating little if any alternative splicing during postembryonic development. Despite many changes in the positions of individual hybridization signals due to the large-scale reorganization of the nervous system, the continuous pattern of gene expression through adult development permitted many adult signals to be identified as larval signals. We concluded that the adult pattern of FMRFamide gene expression was largely derived from persistent larval neurons. Adult-specific hybridization signals in the brain and ventral ganglion were also detected and these corresponded to many of the approximately 40 adult-specific FMRFamide-immunoreactive neurons. One specific larval signal was lost during adult development and the intensities of other signals fluctuated in reproducible manners. These stereotyped differences in hybridization signal intensity resemble similar observations made in larval stages (Schneider et al., '91) and support the hypothesis that the steady-state levels of FMRFamide transcripts are differentially regulated among the diverse neurons that express the gene.

Animals↗

The molluscan cardioactive neuropeptide FMRFamide: subcellular localization in bivalve ganglia.

Ganglia of the mollusk Macrocallista nimbosa were pooled, homogenized, and subjected to differential centrifugation. The neuropeptide Phe-Met-Arg-Phe-NH2 (FMRFamide) was concentrated in the microsomal pellet. When the medium-speed supernatant was centrifuged in a discontinuous sucrose gradient, three separate peaks of activity were detected and identified as acetylcholine, 5-hydroxytryptamine, and FMRFamide. The relative concentration of FMRFamide in each fraction was determined by bioassay and by radioimmunoassay (RIA). Both determinations revealed a peak of peptide in the middle of the sucrose gradient. Electron micrographs of each of the gradient interfaces were analyzed. The interface containing the peak of biological FMRFamide activity was enriched in two- to fivefold in neurosecretory granules with a mean diameter of 104 nm and various electron densities. Morphologically similar vesicles were also seen in intact ganglia. These findings support the notion that FMRFamide is a neurosecretory product. But the physiological function of the peptide in bivalve ganglia remains unknown.

Animals↗

The cyclic GMP-induced inward current in neuron R14 of Aplysia californica: similarity to a FMRFamide-induced inward current.

Injecting cGMP into Aplysia neuron R14 induced an inward current similar to one elicited by application of FMRFamide to the outside of that cell. In contrast, injection of cAMP into R14 caused a long-lasting outward current and conductance increase. Phosphodiesterase inhibitors increased the cGMP and FMRFamide-induced inward currents in R14. The cGMP-induced inward current is voltage dependent and is largely carried by Na+. It is also strongly and inversely dependent on both external [Ca2+] and [Cl-], although these ions are not significant current carriers. Changing external [K+] had no effect. Voltage and ion dependencies of the cGMP-induced inward current are similar to those of an inward current induced by FMRFamide. Thus cGMP may be a second messenger to FMRFamide in producing a slow inward current in R14. cGMP does not appear to be a second messenger to FMRFamide in most Aplysia neurons.

1-Methyl-3-isobutylxanthine↗

FMRFamide-like immunoreactivity in the nervous system of Hydra.

FMRFamide-like immunoreactivity has been localized in different parts of the hydra nervous system. Immunoreactivity occurs in nerve perikarya and processes in the ectoderm of the lower peduncle region near the basal disk, in the ectoderm of the hypostome and in the ectoderm of the tentacles. The immunoreactive nerve perikarya in the lower peduncle region form ganglion-like structures. Radioimmunoassays of extracts of hydra gave displacement curves parallel to standard FMRFamide and values of at least 8 pmol/gram wet weight of FMRFamide-like immunoreactivity. The immunoreactive material eluted from Sephadex G-50 in several components emerging shortly before or after position of authentic FMRFamide. The presence of FMRFamide-like material in coelenterates shows that this family of peptides is of great antiquity.

Animals↗

Detection of FMRFamide-like immunoreactivities in the sea scallop Placopecten magellanicus by immunohistochemistry and western blot analysis.

FMRFamide-like immunoreactivity was detected histochemically in the sea scallop Placopecten magellanicus. Most immunoreactivity was concentrated in the cerebral, pedal, and parietovisceral ganglia, particularly in the cortical cell bodies and in their fibers which extend into the central neuropile. Whole-mount immunofluorescence studies were used to localize concentrations of immunoreactive cells on the dorsal and ventral surfaces of each ganglion. Immunoreactivity was also detected in nerves emanating from the ganglia. Strong immunoreactivity was localized in peripheral organs, including the gut and gills of juvenile and adult scallops. Weak immunoreactivity was detected in the gonads, heart, and adductor muscle of the adults. A broad FMRFamide-like immunoreactive band of 2.5-8.2 kDa was detected by Western blotting of acetone extracts of the parietovisceral ganglia. In the presence of protease inhibitors, two FMRFamide-like immunoreactive bands (7.2-8.2 kDa and > 17 kDa) were obtained. Neither of these bands comigrated with the FMRFamide standard. It is concluded that peptides of the FMRFamide family are probably regulators of numerous central and peripheral functions in P. magellanicus.

Animals↗

FMRFamide-immunoreactive structures in the brain of the brown hagfish, Paramyxine atami: relationship with neuropeptide Y-immunoreactive structures.

Localization of the molluscan cardioexcitatory tetrapeptide FMRFamide (Phe-Met-Arg-Phe-NH2) in the brain and hypophysis of the brown hagfish, Paramyxine atami, was examined by immunohistochemistry specially regarding a possible relationship with neuropeptide Y (NPY). FMRFamide-immunoreactive fibers were demonstrated in many regions of the brain, with the highest density in the diencephalon. However, no immunoreactivity was found in the hypophysis. Labeled cells were chiefly located in the nucleus hypothalamicus of the diencephalon, although a few cells were recognized in the ventrolateral area of the caudal tegmentum. Examination of adjacent sections immunostained alternatively with anti-NPY antiserum and anti-FMRFamide antiserum showed overlapping of the distributional patterns of the immunoreactive structures in the brain. Moreover, the same cells in the nucleus hypothalamicus were immunostained with both antisera. Cross-blocking experiments showed that the FMRF-amide-immunoreactivity is abolished by preabsorption of the antiserum with homologous antigen, but not eliminated completely by pretreatment with appropriate antigens (NPY, avian pancreatic polypeptide and methionine-enkephalin-Arg-Phe). In contrast, the NPY-immunoreactivity was blocked by pretreatment of the antiserum with NPY, pancreatic polypeptide or FMRFamide, although no blocking by enkephalin was observed. Accordingly, the present study shows that, in the brown hagfish, FMRFamide-immunoreactive structures in the brain can be recognized by anti-NPY antiserum.

Amino Acid Sequence↗

A new biological activity for the neuropeptide FMRFamide: experimental evidence for a secretagogue effect on amylase secretion in the scallop Pecten maximus.

FMRFamide immunoreactivity in the digestive tract of the bivalve mollusc Pecten maximus was investigated by immunocytochemistry. Positive FMRFamide-like immunoreactivity was detected in nerve fibres in close contact with exocrine alpha amylase secreting cells. Physiological studies on enzymatically dissociated cells of the stomach-digestive gland complex demonstrated the involvement of FMRFamide and analogues in the control of alpha amylase release from the cells. The FMRFamide-induced secretion was shown to be time- and dose-dependent. In contrast to most naturally occurring vertebrate secretagogues which are hormones, FMRFamide appears to work in our in vitro system as a paracrine factor.

Amino Acid Sequence↗

Identification of Aplysia neurons containing immunoreactive FMRFamide.

Electrophysiological and immunocytochemical techniques were used in the abdominal ganglion of Aplysia to identify neurons containing immunoreactive FMRFamide. Large numbers of neurons were immunoreactive for FMRFamide, including R2, L2, L3, L4, L5, L6, 2 cells tentatively identified as L12 and L13, and a previously unidentified cluster on the ventral surface of the right lower quadrant. There was also heavy labelling of fibers, often with beaded varicosities, throughout the neuropil, the cell layers, and the sheath overlying the ganglion. This data provides further evidence that FMRFamide is an important neurotransmitter in Aplysia. The demonstration of immunoreactive FMRFamide in the giant cholinergic neurons R2 and LP1(1) suggests that these well-studied and experimentally convenient cells use acetylcholine and an FMRFamide-like peptide as cotransmitters.

Animals↗

Supraspinal administration of [D-Met2]FMRFamide produces a naloxone-sensitive increase in heart rate in unrestrained spontaneously hypertensive rats.

Intracerebroventricular (i.c.v.) administration of either Phe-Met-Arg-Phe-NH2 (FMRFamide; molluscan cardioexcitatory neuropeptide; 3-30 micrograms) or the FMRFamide analog Phe-D-Met-Arg-Phe-NH2 ([D-Met2]FMRFamide; 15 micrograms) to conscious unrestrained spontaneously hypertensive rats (SHR) produced a relatively long lasting (greater than 1 h) increase in heart rate. The increase in heart rate produced by [D-Met2]FMRFamide was attenuated by i.c.v. injection of the opiate antagonist naloxone (2 micrograms). These results extend to a second endpoint an apparent opioid agonist-like (naloxone-reversible) action of [D-Met2]FMRFamide.

Animals↗

Supraspinal FMRFamide antagonizes morphine-induced horizontal, but not vertical, locomotor activity.

Morphine and the molluscan neuropeptide Phe-Met-Arg-Phe-NH2 (FMRFamide) were administered to mice alone or in combination intracerebroventricularly (ICV) and the effect on locomotor activity was measured. Morphine given alone (0.5 micrograms) significantly increased horizontal locomotor activity compared to vehicle-treated controls. FMRFamide at low doses (0.01-10 micrograms) had no effect of its own, but blocked the morphine-induced increase in horizontal locomotor activity. Unlike the opiate antagonist naloxone (1.0 micrograms), FMRFamide (up to 10 micrograms) had no effect on morphine-induced decrease in vertical activity. These data further support a role for FMRFamide as a modulator of opiate action, but comparison to naloxone suggests that FMRFamide might not act as a pure competitive antagonist of this opiate effect.

Animals↗

Intrathecal FMRFamide (Phe-Met-Arg-Phe-NH2) induces excessive grooming behavior in mice.

The molluscan neuropeptide Phe-Met-Arg-Phe-NH2 (FMRFamide) was administered intrathecally (i.t.) to mice and their behavior was monitored for 30 min. FMRFamide induced a dramatic and dose-related (5-12 micrograms) increase in grooming-related activities compared to saline-treated controls. The grooming behavior produced by 8 micrograms FMRFamide was not blocked by simultaneous i.t. administration of 10 micrograms of the following antagonists: atropine, phentolamine, methysergide, naloxone or spantide; peripheral administration of naloxone (3.5 mg/kg, s.c.) also failed to antagonize FMRFamide grooming. These data constitute the first report that FMRFamide produces behavioral changes in mammals.

Animals↗